Modality
mAb
MOA
BCL-2i
Target
B7-H3
Pathway
Angiogenesis
ACC
Development Pipeline
Preclinical
~Sep 2013
→ ~Dec 2014
Phase 1
~Mar 2015
→ ~Jun 2016
Phase 2
~Sep 2016
→ ~Dec 2017
Phase 3
Mar 2018
→ Oct 2028
Phase 3Current
NCT06171670
764 pts·ACC
2018-03→2028-10·Active
764 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-10-192.6y awayPh3 Readout· ACC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Active
Catalysts
Ph3 Readout
2028-10-19 · 2.6y away
ACC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06171670 | Phase 3 | ACC | Active | 764 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 |